Dr Reddy's Labs Q2 Results: Profit falls 15% YoY to Rs 1,255 crore, revenue up 17%
Healthcare major Dr Reddy's Labs on Tuesday reported 15% drop in its consolidated net profit at Rs 1,255 crore in the second quarter. It was Rs 1,480 crore in the year-ago quarter.Revenue from operations in the same period stood at Rs 8,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
Healthcare major Dr Reddy's Q2 net profit falls, revenue gains momentum
Healthcare major Dr Reddy's Laboratories reported a 15% decline in its consolidated net profit, totalling ₹1,255 crore for the second quarter of FY25, compared to ₹1,480 crore in the same period last year. However, revenue from operations surged 17% ...
Dr. Reddy’s Q2 net slips to ₹1,342 cr. on record sales
Dr. Reddy’s Laboratories consolidated net profit declined 9.5% for the September quarter to ₹1,341.9 crore compared to ₹1,482.2 crore in the year earlier period even as the generic drugmaker reported revenue from operations raced past ₹8,000 crore for the first time.
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Dr Reddy's clocks highest-ever revenue in Q2; net profit down 9.5%
Hyderabad-based Dr Reddy's Laboratories (DRL) posted a 9.5 per cent year-on-year (Y-o-Y) decline in its consolidated ...
Benzinga.com8h
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Dr. Reddy's Q2 net income dropped to $160 million from $177M YoY, with revenue up 16.6% to $957 million. Global generics revenue grew 17% YoY, driven by sales volume gains and new launches. Dr.
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...
I’m an emergency physician. I know Dr. Prasanth Reddy has it right about health care | Opinion
A recent Star guest commentary wrongly gave readers the impression he rejects health care reform. Set the record straight. | ...
Dr. Reddy’s to expand GLP-1 portfolio with focus on obesity and diabetes drug markets
With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...
Dr Reddys Share Price Today Live Updates: Dr. Reddy's experiences minor price increase
Stay up-to-date with the Dr Reddys Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...
Dr Reddy's R&D expenses to stay around 8.5% in FY25, to launch key biosimilar in 2027
Dr Reddy's ramps up R&D investment with a focus on biosimilars, generics, and biologics, while expecting continued gains from Revlimid amid robust quarterly revenue growth.